Antisense & RNAi Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Antisense & RNAi Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Overview:

The global antisense & RNAi therapeutics market size reached US$ 1.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028.

Antisense therapy is the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It regulates cell function and division and can modulate cellular responses to internal and external stresses and stimuli. It is also used to treat amyotrophic lateral sclerosis and Huntington's and Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. It is employed for treating various respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. RNAi therapy also assists in preventing the production of specific genes that cause diseases or contribute to the growth of diseases.

Antisense & RNAi Therapeutics Market Trends:
The growing demand for antisense and RNAi therapeutics to treat uncommon neurodegenerative diseases, such as hereditary ATTR amyloidosis, represents one of the key factors driving the market. Besides this, there is a rise in the demand for disease management to regulate gene expression by malfunctioning genes across the globe. This, along with the burgeoning healthcare industry, is contributing to the growth of the market. Moreover, key market players are extensively investing in research and development (R&D) activities to develop molecules based on antisense technology. They are also collaborating with contract research organizations (CROs) working on drug delivery, which is strengthening the growth of the market. In addition, the growing demand for antisense RNA to prevent disease onset and reduce disease progression is positively influencing the market. Apart from this, the rising need for curing and preventing diseases, such as cancer, human immunodeficiency virus (HIV), and other diseases caused by mutating viruses is bolstering the growth of the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global antisense & RNAi therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology, route of administration and application.

Breakup by Technology:

RNA Interference
siRNA
miRNA
Antisense RNA

Breakup by Route of Administration:

Intravenous Route
Subcutaneous Route
Intrathecal Route
Pulmonary Delivery
Intraperitoneal Injection
Others

Breakup by Application:

Oncology
Cardiovascular Diseases (CVDs)
Respiratory Disorders
Renal Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S), Ionis Pharmaceuticals Inc., OliX Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Sarepta Therapeutics Inc., Silence Therapeutics and Sirnaomics Inc.

Key Questions Answered in This Report

1. How big is the global antisense & RNAi therapeutics market?
2. What is the expected growth rate of the global antisense & RNAi therapeutics market during 2023-2028?
3. What are the key factors driving the global antisense & RNAi therapeutics market?
4. What has been the impact of COVID-19 on the global antisense & RNAi therapeutics market?
5. What is the breakup of the global antisense & RNAi therapeutics market based on the technology?
6. What is the breakup of the global antisense & RNAi therapeutics market based on the route of administration?
7. What are the key regions in the global antisense & RNAi therapeutics market?
8. Who are the key players/companies in the global antisense & RNAi therapeutics market?